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Abstract. Malaria treatment policy has changed from presumptive treatment to targeted “test and treat” (T&T) with
malaria rapid diagnostic tests (RDTs) and artemisinin combination therapy (ACT). This transition involves changing
behavior among health providers, meaning delays between introduction and full implementation are recorded in almost
every instance. We investigated factors affecting successful transition, and suggest approaches for accelerating uptake
of T&T. Records from 2000 to 2011 from health clinics in Senegal where malaria is mesoendemic were examined
(96,166 cases). The study period encompassed the implementation of national T&T policy in 2006. Analysis showed that
adherence to test results is the first indicator of T&T adoption and is dependent on accumulation of experience with
positive RDTs (odds ratio [OR]: 0.55 [P £ 0.001], 95% confidence interval [CI]: 0.53–0.58). Reliance on tests for malaria
diagnosis (rather than presumptive diagnosis) followed after test adherence is achieved, and was also associated with
increased experience with positive RDTs (OR: 0.60 [P £ 0.001], 95% CI: 0.58–0.62). Logistic models suggest that full
adoption of T&T clinical practices can occur within 2 years, that monitoring these behavioral responses rather than RDT
or ACT consumption will improve evaluation of T&T uptake, and that accelerating T&T uptake by focusing training on
adherence to test results will reduce overdiagnosis and associated health and economic costs in mesoendemic regions.
INTRODUCTION
Global malaria treatment policy has changed from a system
of widespread presumptive treatment based on clinical diagno-
sis of fever to targeted treatment following positive parasito-
logical diagnosis,1 also known as “test and treat” (T&T). The
long-standing practice of presumptive treatment is being
overturned by 1) failure of cheap drugs (i.e., chloroquine,
sulfadoxine/pyrimethamine) and their subsequent replace-
ment with more effective, yet expensive, artemisinin combi-
nation therapies (ACTs), 2) mounting evidence that malaria
only causes a proportion of all fevers in malaria endemic
regions,2,3 and 3) improvements in diagnostic capabilities.
Parasitological confirmation followed by ACT has the poten-
tial to reduce misdiagnosis, improve patient outcomes, and
minimize costs. But this is possible only if T&T policies are
implemented efficiently.
Although 41 out of 45 countries in Africa with malaria
transmission have adopted World Health Organization (WHO)
T&T policies for malaria,4 in practice policy is not consistently
followed. There are many reports of antimalarial treatments
being routinely administered to patients who tested negative
on microscopy5–7 or rapid diagnostic test (RDT).8–11 In addi-
tion, there are many instances where parasitological tests are
available but presumptive diagnosis is still often used for pre-
scription of antimalarials.12–14
T&T policies can now, theoretically, be implemented any-
where because RDTs have significantly expanded testing
capabilities. These tests can help reduce overtreatment of
malaria and associated costs,15 but adherence to test results
must improve if T&T strategies are cost-effective.16 This
potential of RDT programs to reduce unnecessary treatment
has been demonstrated by the reduction in ACT consumption
following introduction of RDTs in some settings.13,17–20
Although RDTs may have no impact on ACT consumption
in areas where microscopy is available,21 their use has been
shown to reduce unnecessary malaria treatments in areas that
previously relied solely on clinical diagnosis,12 but complete
compliance of T&T has yet to be demonstrated.
In Senegal, access to RDTs has improved diagnostic capa-
bilities nationwide and reduced the amount of antimalarials
administered.18 Economic analysis suggested that adoption of
T&T policies could significantly reduce costs associated with
malaria in the region—if adherence to test results was consis-
tent.22 Despite these positive reports, delays between the
introduction of T&T policies and consistent usage and trust
in the results of RDTs demonstrate that there is a need to
examine if febrile patients may be managed more effectively.
Our objective was to identify factors influencing the time
course of behavioral changes following new T&T policies in
mesoendemic regions of Senegal. Specifically, we quantified
the delay between the introduction of policies and uptake in
six community health centers, as well as the process of conver-
sion to RDT-based treatment. Characterizing the length of this
delay and the factors that affect the rate of change in testing
behavior is important for evaluating whether T&T policies
have been effectively “rolled out” or require additional train-
ing and support to be effective. Understanding the sequence of
changes that precedes full adoption of T&T policies will help to
highlight behaviors that are important for monitoring in areas
where implementation has been less successful, and suggest
areas of focus to speed uptake of new policies.
MATERIALS ANDMETHODS
Study sites. Complete, detailed, and anonymous clinical
data on consultations, fevers, malaria tests and results, and
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treatments were available from five dispensaries in the Dis-
trict of Oussouye, in the southern Casamance region of south-
west Senegal, and one dispensary in Toucar (District of
Niakhar, in western Senegal) (Table 1). Each dispensary is
run by a nurse who is supported by a technician and health
workers. The outpatient clinic of Oussouye is housed in the
local hospital. A district medical doctor is based in each clinic
in Oussouye and Niakhar.
Malaria in these areas is mesoendemic, with an increase of
cases during the rainy season (July–December). Interventions
to reduce malaria burden have included insecticide-treated
nets, indoor residual spraying, and chemotherapies. In the
District of Oussouye, malaria risk has dramatically dropped
over a 15-year period, and there is no longer a clear age
prevalence signature.23
A series of policy changes in the diagnosis and treatment of
malaria cases took place in this region (Figure 1). In Senegal,
the national T&T policy was enacted in 2006. In Oussouye
district, two pilot phases preceded national policy in Mlomp
(2000–2005)22,24,25 and Djembereng (2002–2005), during which
diagnostics (microscopy on thick, counting 200 WBCs, and
thin blood smears), treatment (artesunate plus amodiaquine
[ASAQ]), and training were provided without cost. All
malaria treatments were administered under the supervision
of a nurse, and the nurses were trained for 3 days prior to the
start of pilot phase to demonstrate protocols for ASAQ treat-
ment administration.
Measuring T&T policy uptake. The goals of T&T policies
are to reduce overtreatment of malaria, encourage correct
diagnosis, and reduce costs associated with misdiagnosis. We
disentangled this decision process into several behaviors that
can be objectively measured from clinical records and concep-
tualized as a decision tree (Figure 2). At the root of this tree is
the initial decision of a health provider to test a patient pre-
senting with fever for the presence of malaria parasites,
P(testjfever); (it literally translates to the probability of test-
ing given a patient with a fever). Conditional on the decision
whether to use a test for a febrile patient, the provider then
has to make the decision to treat. We denoted the probability
of prescribing antimalarial treatment among individuals not
administered a test as P(treatjno test)—when this is equal to
1 prescribers are exclusively using presumptive diagnosis to
treat febrile patients, whereas when this is equal to 0 pre-
scribers are only administering treatment to tested individuals.
Among those who were tested for malaria, we denoted the
probability of treatment of individuals with a positive test as
P(treatjpos. test), with a negative test as P(treatjneg. test). We
defined optimal adherence to T&T as P(treatjno test) = 0,
P(treatjpos. test) = 1, and P(treatjneg. test) = 0. In words,
the objectives of malaria T&T policy are to test all suspected
cases of malaria, treat all positive test results, and not treat
negative malaria cases with antimalarials. These probabilities
can be used for evaluation in any setting to determine effec-
tiveness of policies.
To understand treatment decisions in detail, we also ana-
lyzed the types of antimalarial treatments prescribed to
patients. ASAQ (a type of ACT) has been the recommended
first-line treatment since 2006, but other antimalarials were
available at dispensaries (including chloroquine, quinine, and
AQ/sulfadoxine/pyrimethamine [SP]), despite resistance. We
Figure 1. Timeline of malaria policies in Senegal. This timeline illustrates the changes in malaria policies over the period of 2000–2012. Prior to
a “test and treat (T&T)” national policy in 2006, malaria was diagnosed by clinical symptoms (usually fever). Over the same time frame the
recommended first-line treatment changed from 1) chloroquine (CQ) or intramuscular quinine (IM Q) to 2) amodiaquine (AQ) plus sulfadoxine/
pyrimethamine (SP), and finally 3) artesunate plus amodiaquine (ASAQ), a type of artemisinin combination therapy (ACT). Parasitological
diagnosis was made by microscopy on Giemsa-stained thick and thin smear until 2007, when rapid diagnostic tests (RDTs) were made available at
all sites. Both RDTs and ACTs were made freely available starting in 2010. The two pilot studies are also shown in grey.
Table 1
Summary of dispensaries
Dispensary Population Data availability Introduction of RDTs Introduction of ACTs
Health-seeking behavior
(consult/person/year)
Wet season fevers, earliest*
(fevers/person/month)
Wet season fevers 2011
(fevers/person/month)
Mlomp 7,600 Jan-00 Jan-07 Jan-00 0.73 (0.67–0.79) 0.52 0.14
Djembereng 2,858 Jan-00 Jan-07 Oct-02 0.86 (0.79–0.92) 0.29 0.15
Elinkinde 3,547 Sept-01 Oct-07 Jan-06 0.86 (0.78–0.93) 0.41 0.12
Kabrousse 3,489 Jan-06 Jan-07 Jan-06 1.17 (1.11–1.24) 0.36 0.13
Oussouye† 7,883 Aug-05 Jan-07 Aug-05 0.33 (0.28–0.36) 0.10 0.07
Toucar 3,150 Dec-01 Nov-07 May-06 1.42 (1.26–1.57) 0.47 0.76
ACTs = artemisinin combination therapy; RDTs = rapid diagnosis tests.
This table summarizes the data available from each dispensary. All health clinics are in Oussouye district, except Toucar, which is in Niakhar district.
*Wet season fevers were calculated as the average number of fevers during the earliest wet season with complete data.
†Oussouye has three dispensaries, we only used the Tri dispensary as it had the most complete dataset. This is why the consultation load is so much smaller than the other dispensaries.
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examined the probability of ACT administration compared
with other antimalarials prescribed, P(ACTjantimalarials).
These treatments included individuals that received antima-
larials regardless of testing or outcome of the test.
Statistical analysis.We first tested these data to see whether
behavioral responses were well described by a logistic model
(Supplemental Equation 1). The logistic model is useful for
describing the rate of change from one regimen to another,
for example, the change from presumptive diagnosis to a full
T&T regime. Parameters describing the rate of change and
the midpoint of the transition were estimated for each dispen-
sary and response via Markov chain Monte Carlo (MCMC)
using PyMC 2.326 in Python 2.7.4. Data for two clinics were
available for every month from 2000 to 2011 (Mlomp and
Djembereng), while the remaining clinics cover subsets of this
period (Table 1).
To evaluate factors that affected the timing and rate of tran-
sition, we fitted logistic regression models to the data using the
generalized linear model function (glm) in R version 3.0.2
(Vienna, Austria).27 All districts were analyzed together, the
outcome responses are behaviors bolded in Figure 2 and
P(ACTjantimalarials). Models were chosen using Akaike
information criterion (AIC).28 Adjusted odds ratios (ORs)
were calculated for the best-fit models.
Predictor variables and model selection are described in
detail in the supplementary material, but we will briefly men-
tion important predictors here. Data from each month were
available—so predictor variables reflect cumulative monthly
values. Data that showed significant seasonality were normal-
ized as anomalies (Supplemental Figures 1 and 2)—for example,
rainfall anomalies were calculated by finding the mean rain-
fall and monthly anomalies represented standard deviations
from this mean. Because patient load, treatment seeking
behavior, and timing of RDT availability varied significantly
between district health centers, we used relative accumulation
of tests as a proxy for experience with RDTs and/or micros-
copy. For example, accumulation of positive tests (RDTs plus
microscopy tests) was calculated for each district by summing
the number of positive tests over the entire period, then divid-
ing the cumulative positive tests each month by that sum of all
positive tests. Values were then multiplied by 10, so that each
unit increase represented a 10% accumulation of positive tests
and gave a more interpretable metric (Supplemental Table 1
and Supplemental Figure 3).
Ethics. The pilot intervention study was approved by the
Ethic Committee of Institut Pasteur of Dakar. The collection
of anonymous administrative data was conducted under the
authority of the district medical officer, as required locally.
The funding sources of the study had no role in study design,
data collection, data analysis, data interpretation, or writing
of the report.
RESULTS
Transitions to T&T. The logistic model was appropriate to
describe the transition of some clinical behaviors, but not for
all outcomes or districts. It accurately described the transition
from zero to full adherence of test results (P(treatjneg. test) = 1)
in Mlomp, where a pilot study took place (Figure 3A); this
transition began before national policies and took almost
Figure 2. Decision tree for application of test and treat (T&T)
policies. Entries in the tree reflect conditional relationships between
provider behaviors. For example, the decision to administer antima-
larials to an individual with a positive test (pos. test) is conditional
on the probability of administering a malaria test. Bolded entries in
the tree indicate provider decisions included in our analysis. “Treat”
refers to only treatment with antimalarials and not any other chemo-
therapy (i.e., antibiotics).
Figure 3. Transitions in clinical behavior. (A) Adherence to
rapid diagnosis test (RDT) results in Mlomp, Senegal. The points on
the graph represent the proportion of cases with negative RDTs, who
received antimalarials. The proportion begins to drop during the pilot
phase, but complete adherence is not obtained until 2009. The trend is
well represented by a logistic model. (B) Proportion of clinically
diagnosed cases receiving antimalarials: non-pilot clinics. The propor-
tion of untested febrile cases that are treated with antimalarials drops
significantly in all four districts and the rapid change in behavior can
be represented with a logistic model.
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4 years for saturation (complete and sustained adherence to
test results). In other districts, there was no clear transition
from a regime in which treatment decisions were not depen-
dent on test results to one where they consistently followed
test results. However, accumulation of positive RDT results
was a strong predictor of behavior change (Table 2 ; OR: 0.55
[P < 0.001], 95% confidence interval [CI]: 0.53–0.58), which
positively correlated with time (see Supplemental Figure 2)
and indicated that a similar mechanism may account for these
changes in adherence across districts.
The transition to consistent reliance on testing (P(treatjno
test)) was well described by the logistic regression in
Djembereng, Elinkinde, Kabrousse, and Toucar (Figure 3B).
The transition period lasted between 12 and 24 months.
Change in the probability of testing fevers was not well
described by the logistic regression; testing rates fluctuated
over time and were determined by many factors (Figure 4
and Table 2).
Clinical behavior in detail. Testing behavior, P(testjfever),
represents the initial decision made by a health provider when
presented with a febrile patient. To comply with T&T guide-
lines, health providers should test patients before they treat
with antimalarials, but because only a portion of fevers are
malaria cases, testing all febrile cases is not necessary for T&T
compliance. National T&T policies (OR: 16.72 [P < 0.001];
95% CI: 13.39–21.18), pilot phases (OR: 73.16 [P < 0.001];
95% CI: 58.66–92.64), availability of RDTs (OR: 5.60
[P < 0.001], 95% CI: 5.05–6.22), and monthly rainfall (OR:
1.13 [P < 0.001]; 95% CI: 1.11–1.14, per one standard devia-
tion increase of rain [~17 cm]) all increased the probability
of testing febrile cases (Table 2). Accumulating experience
with positive tests (both RDTs and microscopy) increased
testing (OR: 1.17 [P < 0.001], 95% CI: 1.16–1.18), but this
effect was diminished when there was access to RDTs
(Figure 4B). The model suggested that health practitioners
are relying on seasonal environmental cues (rainfall) to
supplement national and local policies when deciding to
test patients. Although testing initially increased, it even-
tually decreased over time, potentially influenced by the
declining number and proportion of positive malaria cases
(Supplemental Figure 4).
In all districts, cases with a positive test result (either
microscopy or RDTs) were always treated with antimalarials.
In addition, cases that tested negative for malaria were rarely
released without some intervention, either antimalarials, anti-
biotics, antipyretics or other treatment (Figure 5). The proba-
bility that health providers will still treat negative test results
with antimalarials increased with febrile cases in that month
(OR: 1.90 [P < 0.05], 95% CI: 1.75–2.07) and during pilot
phases (OR: 28.00 [P < 0.001], 95% CI: 22.45–35.09) (Table 2).
This means that clinicians were assimilating local information,
such as pilot phases or case load, and used it to overrule test
results. However, accumulation of provider experience with
reliable measurements (accumulation of positive RDTs was
used as a proxy) decreased the probability of administering
antimalarials to negative individuals (OR: 0.55 [P < 0.001],
95% CI: 0.53–0.58). It is tempting to conclude that increased
experience with positive RDTs reinforced health practitioners
trust in the results, and lead to adherence to test results.
Accumulation of test results was not linear (see Supplemental
Figure 3) and was the best predictor in multivariate models,
suggesting that the experience with positive tests rather than
just time is important for promoting adherence. Because
microscopy diagnostics were prevalent during the pilot
phases, it is difficult to disentangle if the usage of microscopy
impacted the probability of treatment of negative tests com-
pared with RDTs.
The last behavioral transition is the abandonment of
presumptive diagnosis for malaria cases. In all of the dis-
pensaries, complete dependence on parasitological tests,
Table 2
Best-fit multivariate models for monthly clinical behaviors observed. The covariates of the multivariate GLM with the lowest AIC score are listed
Variable
P(testjfever) P(treatjneg. test) P(treatjno test)
OR (95% CI) OR (95% CI) OR (95% CI)
Intercept 0.005** (0.004–0.006) 0.05** (0.03–0.07) 34.07** (29.16–39.98)
Epidemiological
Fevers (anomalies)† − 1.90* (1.75–2.07) 1.19** (1.16–1.22)
Environmental
Rainfall (anomalies)† 1.13** (1.11–1.14) − −
Policy
Pilot phase (binary) 73.16** (58.66–92.64) 28.00** (22.45–35.09) 1.30** (1.15–1.46)
T&T policy (binary) 16.72** (13.39–21.18) − −
Testing
RDT availability (binary) 5.60** (5.05–6.22) 4.19** (3.22–5.46) 0.47** (0.41–0.54)
Accum of pos. RDTs‡ 0.55** (0.53–0.58) 0.60** (0.58–0.62)
Accum of pos. tests‡ 1.17** (1.16–1.18) − −
Binary RDT Accum pos. tests* 0.80** (0.79–0.81) − −
Dispensaries
Djembereng − − −
Elinkinde 0.39** (0.35–0.43) 1.05 (0.60–1.82) 1.02 (0.85–1.24)
Kabrousse 1.38** (1.28–1.48) 1.38 (0.60–2.86) 3.10** (2.52–3.83)
Mlomp 2.39** (2.26–2.52) 30.31** (21.07–43.57) 0.031** (0.027–0.036)
Oussouye 1.01 (0.92–1.12) 47.03** (30.94–71.57) 0.38* (0.30–0.47)
Toucar 0.98** (0.91–1.05) 0.21** (0.07–0.50) 3.10* (2.43–3.95)
Accum of pos. = accumulation of positive; AIC = Akaike information criterion; CI = confidence interval; GLM = generalized linear model; neg. = negative; OR = odds ratio; RDTs = rapid
diagnosis test; T&T = test and treat policy.
Significance is indicated at *P £ 0.05; **P £ 0.001.
†Anomalies are determined by the standard deviations around the mean (see Supplemental Information and Supplemental Figures 1 and 2).
‡Accumulation is determined by dividing the number of tests in the clinic at that date divided by all tests given in the study period and multiplied by 10. One unit represents 10% of the total
number of tests. Used instead of raw numbers to normalize across clinics (Supplemental Figure 3).
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P(treatjno test) = 0), followed full adherence to test results,
P(treatjneg. test = 0). Monthly fevers greater than average
increased the likelihood that an untested individual (OR:
1.19 [P < 0.001], 95% CI: 1.16–1.22) or one with a negative test
(OR: 1.90 [P < 0.05], 95% CI: 1.75–2.07) received treatment.
Health practitioners were using local febrile patient loads to
help access the risk of malaria—this made sense when malaria
was major causative agent for malaria, and reflects the history
of presumptive diagnosis. However, availability of RDTs (OR:
0.47 [P < 0.001], 95% CI: 0.41–0.54) and increased experience
with positive RDTs significantly decreased reliance on pre-
sumptive diagnosis (OR: 0.60 [P < 0.001], 95% CI: 0.58–0.62).
Figure 5. Treatment of negative fever cases. The treatment of negative fever cases changes drastically over time. We show proportion
treatments in each class that are given to negative malaria patients. To simplify the figure, data are shown by season rather than monthly. Until
national test and treat (T&T) policies in 2006, almost all negative malaria treatments received some kind of antimalarial. A year after the national
T&T policy, antibiotics begin to be administered to fevers negative for malaria and the proportion increases as time progresses. In addition, fevers
were rarely released without some form of treatment.
Figure 4. Testing of febrile cases. (A) The best-fit logistic regression model for P(testjfever) is shown in for all of the districts. The line is the
model, whereas the points are the data. (B) Although testing rates are initially high, the probability of testing a febrile case decreases over time,
likely reflecting the realization that only a portion of fever cases are caused by malaria.
ADOPTION OF MALARIA TEST AND TREAT POLICY 163
Again, pilot phases negatively impacted behaviors and actu-
ally increased the probability of treating untested individuals
(OR: 1.30 [P < 0.001], 95% CI: 1.15–1.46).
Choice of antimalarials. The frequencies of ACT admin-
istration compared with other antimalarials prescribed,
P(ACTjmalaria treatment), varied over time and between
clinics. The overall trend was fewer total antimalarial treat-
ments over time and increased proportion of ACTs that were
administered; however, none of the districts prescribed 100%
antimalarials as ACTs (Figure 6). Monthly fever cases (OR:
1.31 [P < 0.001], 95% CI: 1.29–1.34; for each 1 standard devia-
tion increase in fever cases), national T&T policy (OR: 336.83
[P < 0.001], 95% CI: 257.47–348.01), and pilot phases (OR:
257.22 [P < 0.001], 95% CI: 194.29–348.01) were all associated
with increased ACT usage (Table 3). There was also a time
effect: accumulating experience with positive tests (RDTs and
microscopy) increased the probability of using ACTs over
other antimalarials (OR: 1.33 [P < 0.001], 95% CI: 1.32–1.35).
We emphasize that only treating fever cases that test positive
for malaria is not mutually exclusive with complete usage of
ACTs. Non-ACTs were still administered after health pro-
viders fully relied on parasitological diagnosis, suggesting that
ACT consumption is not an accurate metric of T&T uptake.
DISCUSSION
Our modeling results showed that adoption of malaria T&T
policies can occur swiftly and completely once initial health
provider reluctance is overcome. Experience with positive RDT
results was pinpointed as a significant predictor in adherence
to test results, which was followed by the abandonment of
presumptive diagnosis. The monitoring methods that we devel-
oped focus on key decisions of health providers and allowed
accurate evaluation of behavior change following T&T intro-
duction (Figure 2). Evaluating these decisions and factors that
influence them, rather than ACT or RDT consumption, bet-
ter quantifies T&T uptake and highlights key factors contrib-
uting to adoption of T&T.
Other studies across a diversity of epidemiological and
social settings have emphasized inefficiencies in T&T adop-
tion.10,29 Our study demonstrates successful uptake of the
T&T strategies, and importantly, show that a delay in initial
uptake of testing does not indicate that complete adoption of
T&T behaviors will not occur, confirming another study
showing improvement years after T&T introduction.30 Many
T&T evaluation studies have been conducted over a relatively
short period (12–18 months), which is most likely inadequate
to demonstrate T&T uptake.12,31 If other areas follow similar
behavioral transitions as Senegal, then change is character-
ized by a rapid switch in behavior after an initial delay that
may last years (Figure 3). Long-term monitoring is essential
to determine the success of T&T, and more research should
focus on the inertia contributing to initial delays.
With T&T guidelines, practitioners must first decide whether
to test a patient for malaria and then, presumably on the
basis of the test result, decide whether and with what to
Figure 6. Artemisinin combination therapy (ACT) usage. The total number of ACTs increases (gray bars) immediately after the national test
and treat (T&T) policy is enacted, as does the proportion of antimalarials that are ACTs (black line). However, the proportion of ACTs
administered does not equal 1.0 during the study period, even when all clinics are following T&T policies (indicated by gray arrow), in fact,
proportion of ACTs decreases after clinical behaviors adhere to T&T guidelines.
Table 3
Best-fit model for probability of ACT administered as antimalarial
Fixed effects
P(ACTjantimalarials)
OR (95% CI)
Intercept 0.0005** (0.0003–0.0006)
Epidemiology
Fever (anomalies) 1.31** (1.29–1.34)
Policy
T&T policy (binary) 336.83** (257.47– 348.01)
Pilot phase (binary) 257.22** (194.29–348.01)
Testing
Accum pos. tests 1.33** (1.32–1.35)
Dispensaries
Djembereng
Elinkinde 16.12** (13.98–18.61)
Kabrousse 7.71** (6.82–8.73)
Mlomp 0.25** (0.23–0.28)
Oussouye 15.10** (12.40–18.48)
Toucar 3.27** (2.90–3.70)
Accum of pos. = accumulation of positive; ACT = artemisinin combination therapy;
CI = confidence interval; OR = odds ratio; T&T = test and treat policy.
The covariates of the multivariate generalized linear model (GLM) with the lowest Akaike
information criterion (AIC) score were fit for P (ACT/antimalarials).
Significance is indicated at **P £ 0.001.
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treat the patient. Measuring health providers propensity to
test a febrile patient (P(testjfever)) was not a good indicator
of T&T adoption because testing of febrile cases was compli-
cated by the realization that many fevers are not caused by
malaria. In the clinics we evaluated, adherence to test results
(P(treatjneg. test) = 0) was the first indicator that health pro-
viders are adopting T&T policies. This is a better indicator of
T&T adoption than ACT or RDT consumption and is fortu-
nately relatively simple to monitor. Reliance on tests for
malaria diagnosis (P(treatjno test) = 0), or abandonment of
presumptive diagnosis, followed after full adherence to RDT
results was achieved.
By looking at several types of provider responses to T&T
policies, we find that policy makers, as well as implementing
and funding agencies, should focus on adherence and reliance
on parasitological tests rather than ACT or RDT consump-
tion to monitor the successful implementation of T&T. We
clearly showed that adoption of T&T clinical behaviors before
ACT usage was 100% (it is actually never achieved), and also
demonstrated that treatment of untested and negative results
with ACTs inflates this metric. In addition, usage statistics of
RDTs is problematic because adherence to these results varies
greatly.8–11 RDT consumption reflects the act of testing,
rather than adherence to the result.
Furthermore, these modeling results revealed factors that
are important in influencing crucial behavioral changes. Con-
sistent across all behaviors, increased exposure to positive
parasitological test results allow health providers to reevaluate
their perceived risk and adopt T&T strategies. This increased
experience (measured as accumulation of positive RDTs and/
or microscopy results) was a better predictor than simply time
since policy introductions or beginning of pilot studies. Accu-
mulation of positive RDTs, which measures exposure of prac-
titioners to positive results, significantly improved both
adherence to test results and reliance on parasitological diag-
nosis. Exposure to microscopy results increased testing of
febrile cases, but did not have a direct effect on the crucial
behaviors of adherence or reliance. Resources should be
spent encouraging adherence to test results by exposing
health practitioners to tests results through workshops and
incentives for using RDTs within their clinic.
Several policies were influential in affecting testing and
treatment behavior, although not always in their intended
manner. National policies increased testing rates, most likely
driven by an increase in testing in non-pilot districts. Pilot
phases, which were a precursor to national guidelines, were
effective in encouraging testing and treating individuals, but
the result of the test (or the absence of a test) did not influ-
ence the decision to treat. Thus, the pilot phases were not
necessary for T&T adoption—in our study they encouraged
overtreatment. Pilot phases were not monitored for adher-
ence, which may influence their effectiveness, and more oper-
ational research is needed before any particular claims are
made about the effectiveness of pilot phases. Finally, it is of
importance that freely available RDTs and ACTs were not
significant in the adoption of T&T policy. T&T policies were
already adopted in most of the districts when resources were
made freely available and were not significant in the adoption
of these policies.
Although external factors affected T&T adoption (i.e.,
national T&T Policy, RDT availability), local factors were
still very important in influencing all decisions. Seasonal
factors, including anomalies in monthly rainfall and fever
cases, influenced health decisions. Testing decisions follow
rainfall, which varies little between years but has very distinct
seasonal patterns within a year (Supplemental Figure 1), but
treatment decisions follow monthly fever cases, which exhibit
similar seasonality but a decreasing trend over time in some
districts (Supplemental Figure 2). Both factors are noninva-
sive assessments of malaria risk and without parasitological
confirmation (or doubt in tests results); health providers can
use these metrics as indicators of malaria risk. These seasonal
factors had a significant influence on decision making, espe-
cially in the absence of parasitological diagnostics, and may
contribute to the long lag time in adoption of T&T.
An unfortunate unintended consequence of adoption of
T&T policies is the over prescription of antibiotics.3,29
Although the majority of negative malaria tests are no longer
treated with antimalarials beginning in 2006 (Figure 5), there
is a significant increase in antibiotics (amoxicillin, doxycy-
cline, ampicillin, cloxacillin, tetracycline, and others). This
increase is unsurprising given global trends in antibiotic con-
sumption,32 but is a cause for concern. Blanket prescriptions
for antibiotics should be avoided to preserve antibiotic effi-
cacy and prolong development of local resistance. We do not
know the true causative agents of fevers in this region and
more work should be carried out to determine appropriate
diagnosis and treatments in lieu of declining malaria.
This study is not without limitations. We are unable to test
if stock outs play an important role in T&T adoption, as has
been reported in other studies,33,34 and is most likely a signif-
icant challenge for many areas where T&T is being
championed. Our data also does not allow us to determine
the effect that the policy has had on overall morbidity for
malaria. Although malaria incidence dropped dramatically
over time and more so concomitantly with the use of ACT,13
we cannot be certain that there is a causal relationship
between adoption of T&T and decreased malaria incidence.
If malaria continues to decline, and testing rates are of only a
portion of febrile patients, increasingly rare malaria cases may
be missed despite the high sensitivity and specificity of the
histidine-rich protein 2 (HRP2)–type RDTs (used in Senegal).35
Missed malaria cases pose a challenge for malaria eradication
and may eventually affect confidence in T&T policies and
lead to practitioners reverting to presumptive diagnosis.
Our analysis relied on data from a small number of clinics,
despite this, we anticipate the results to hold for many other
clinics. The difference between the districts was no greater
than the variability within each district (Table 2). Models
suggest consistent and significant predictors, even though
there is heterogeneity in individual and clinic-level responses
to new policies and individual patient symptoms affect eventual
diagnosis and treatment.36 Complete T&T adoption occurred
in Senegal with an increase in experience with positive malaria
tests, along with national policies and RDT availability.
National T&T policies are widespread among malaria
endemic countries, but adherence to these policies is limited.
Our results are the first to demonstrate full adoption of T&T
policies for malaria by individual health clinics. Although
there may be delays from RDT availability to initial usage,
our model results suggested that belief in the accuracy of
RDTs and treatment based on RDT results was a critical
factor in the effectiveness of T&T policies and lead to quick
abandonment of presumptive treatment. Experience with
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positive RDT results was a significant predictor of adoption of
T&T policies; therefore, focusing efforts on promoting adher-
ence to parasitological tests through practice with RDTs will
accelerate T&T uptake and reduce overdiagnosis.
Delays in consistent testing and poor adherence following
RDT availability should prompt interventions targeted at
behavior of individual providers. Policymakers, malaria pro-
gram managers, and implementing and funding agencies
should focus on this lag between RDT availability, initial
provider uptake, and the rate of adherence to RDT results
when they are used. Further research is necessary to understand
the social and behavioral factors driving delays from RDT
availability to initial uptake. Such research will be critical for
designing education and incentives that can effectively
encourage early RDT usage and adherence. This focus should
limit overtreatment, improve T&T adoption, and reduce costs
as countries move toward the new Test, Treat, Track direc-
tives of WHO.
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